Trial Profile

A RANDOMIZED, MULTICENTER, LONG TERM STUDY OF THE SAFETY OF TANEZUMAB IN PATIENTS WITH CHRONIC LOW BACK PAIN

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 09 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tanezumab (Primary) ; Tanezumab (Primary)
Indications Back pain
Focus Adverse reactions; Registrational; Therapeutic Use
Sponsors Pfizer

Most Recent Events

11 May 2013 Results from an extension trial presented at the 32nd Annual Scientific Meeting of the American Pain Society.
23 Dec 2010 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
19 Jul 2010 Status changed from recruiting to suspended, based on a Pfizer media release. Adverse events were noted tanezumab recipients with osteoarthritis, and the FDA requested suspension based on the potential for adverse events in other patient populations.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com